Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Study to Assess the Efficacy and Safety of Alipogene Tiparvovec (AMT-011), Human LPL [S447X], Expressed by an Adeno-Associated Viral Vector After Intramuscular Administration in LPL-deficient Adult Subjects

NCT00891306 is registered in ClinicalTrials.gov with Amsterdam Molecular Therapeutics as lead sponsor.

NCT NCT00891306
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00891306 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Study to Assess the Efficacy and Safety of Alipogene Tiparvovec (AMT-011), Human LPL [S447X], Expressed by an Adeno-Associated Viral Vector After Intramuscular Administration in LPL-deficient Adult Subjects
Lead sponsor
Amsterdam Molecular Therapeutics
Phase
Phase 2/3
Overall status
Completed
Start date
February 28, 2009
Completion date
April 30, 2011
Enrollment
5 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

familial lipoprotein lipase deficiency